3National Comprehensive Cancer Network.2009 NCCN clinical practice guidelines for breast cancer,Version 1.http:// www.nccn.org.2009.
4O'Shaughnessy J,Miles D,Vukelja S,et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:Phase Ⅲ trial results.J Clin Oncol,2002,20:2812-2823.
5Cardoso F,Bedard PL,Winer EP,et al.International guidelines for management of metastatic breast cancer:combination vs sequential single-agent chemotherapy.J Natl Cancer Inst,2009,101:1174-1181.
6Stockler M,Sourjina T,Grimison P,et al.A randomized trial of capecitabine (C) given intermittently (IC) versus continuously (CC) versus classical CMF as first line chemotherapy for women with advanced breast cancer (ABC) unsuited to more intensive treatment.J Clin Oncol,2007,25(18S):1031.
7Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med,2001,344:783-792.
8Marty M,Cognetti F,Maraninchi D,et al.Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group.J Clin Oncol,2005,23:4265 -4274.
9Jackisch C.HER-2-Positive metastatic breast cancer:Optimizing trastuzumab-based therapy.Oncologist,2006,11:34-41.
10Wardley AM,Pivot X,Morales-Vasquez F,et al.Randomized phase Ⅱ trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.J Clin Oncol,2007,25:1031.
1Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 2001, 27:165-176.
2Johnson JR, Williams G, Pazdur R, et al. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol, 2003, 21 : 1404-1411.
3Kinnane N. Burden of bone disease. Eur J Oncol Nuts, 2007, 11 Suppl 2 : S28-31.
4Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 2005, 35:84-99.
5Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 2007, 25: 1423-1436.
6Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oneology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oneol, 2003, 21:4042-4057.
7Weitnnan R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol, 2007, 62:148-152.
8Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J CIin Oncol, 2005, 23:4925-4935.
9Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.
10Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase Ⅱ trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oneol, 2006, 24:4895-4900.
7Johnston SR.New strategies in estrogen receptor-positive breast cancer[J].Clin Cancer Res,2010,16(7):1979-1987.
8Guarneri V,Barbieri E,Dieci MV,et al.Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer[J].Cancer Treat Rev,2010,36(3):$62-$66.
9Giampaglia M,Chiuri VE,Tinelli A,et al.Lapatinib in breast cancer:clinical experiences and future perspectives[J].Cancer Treat Rev,2010,36(3):S72-S79.
10Carpini JD,Karam AK,Montgomery L.Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast,ovarian,and cervical cancer[J].Angiogenesis,2010,13 (1):43-58.
